TMO vs MRK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TMO · Thermo Fisher Scientific$694.76 ▲ 2.63%
MRK · Merck & Co$146.73 ▼ 0.14%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TMO +20.9%
- MRK +73.1%
Head to head
| Metric | TMO | MRK |
|---|---|---|
| Price | $694.76 | $146.73 |
| Change today | ▲ 2.63% | ▼ 0.14% |
| Market cap | $257.42B | $361.73B |
| Return, 3 months | +15.9% | +12.1% |
| Return, year to date | +20.1% | +41.4% |
| Return, 1 year | +21.7% | +74.0% |
| P/E (TTM) | 36.6 | 148.2 |
| P/B | 4.7 | 8.1 |
| P/E percentile vs own 5y | 88th | 95th |
| Dividend yield | 0.26% | 2.32% |
| Revenue growth (YoY, latest qtr) | +9.1% | +4.7% |
| Net profit growth (YoY) | +6.5% | -12.4% |
| Gross margin | 41.4% | 71.8% |
| Operating margin | 18.7% | 9.2% |
| Net margin | 14.9% | 3.6% |
| Return on equity | 13.4% | – |
| Analyst target vs. price | +12.0% | +14.1% |
| Analyst buy share | 93% | 79% |
| RSI (14) | 55 | 51 |
| 30-day volatility | 30.6% | 33.2% |
| Max drawdown, 1 year | -31.4% | -11.4% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MRK is the largest of the group by market value.
- MRK has returned the most over the past year.
- TMO carries the lowest trailing P/E.
- MRK pays the highest dividend yield.
- TMO is growing revenue fastest.
- TMO keeps the most profit per dollar of sales.
- TMO has been the calmest stock over the last 30 days.